



Name **Wen-Chin
Huang (黃文欽)**

Current Positions

Associate Professor
International Master's
Program of Biomedical
Sciences
China Medical University
Taichung, Taiwan

Telephone

+886--4-22052121 ext. 7721

E-mail

huangwc@mail.cmu.edu.tw

E-Portfolio Website

http://webap.cmu.edu.tw/TchEportfolio/index_1/huangwc

Personal Website

Education

National Taiwan University, Taipei, Taiwan (PhD)

Emory University, Atlanta, GA, USA (Post-doctoral fellow)

Expertise

- Prostate tumor
- Metabolism
- Targeted therapy
- Signaling transduction
- microRNA

Research Interests

My laboratory is interested in the study of lipid and cholesterol metabolism/biosynthesis in prostate cancer progression. Specifically, we focus on the master transcription factors, sterol regulatory element-binding proteins (SREBPs), for lipogenesis and cholesterol synthesis. Additionally, we attempt to develop small chemical molecules and natural compounds as well as Chinese herbal products as potential anti-cancer drugs.

Selected Grants:

1. MOST 106-2320-B-039-058. The innovative roles of SREBP-2 in lethal prostate cancer aggressiveness. 2017.08.01 ~ 2018.07.31.
2. NHRI-EX-10901BI, SREBP-1 in prostate cancer progression and therapeutic intervention. 2020.01.01 ~ 2022.12.31.

Selected Publications

1. Hsieh, P.F., Jiang, W.P., Huang, S.Y., Basavaraj, P., Wu, J.B., Ho, H.Y., Huang, G.J., and Huang, W.C. Emerging therapeutic activity of *Davallia formosana* on prostate cancer cells through coordinated blockade of lipogenesis and androgen receptor expression. *Cancers*, 12(4):914, 2020.
2. Huang, S.Y., Huang, G.J., Hsieh, P.F., Wu, H.C., and Huang, W.C. Osajin displays potential anti-prostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression *Prostate*, 79: 1543-52, 2019.
3. Rotinen, M., You, S., Yang, J., Coetzee, S., Reis-Sobreiro, M., Huang, W.C., Huang, Pan, X., Yanez, A., Hazelett, D., Chu, C., Steadman, K., Morrissey, C., Nelson, P., Corey, E., Chung, L., Freedland, S., Di Vizio, D., Garraway, I., Murali, R., Knudsen, B., and Freeman, M. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. *Nature Medicine*, 24: 1887-98, 2018.

Selected Patents